Dr Reddy's issues clarification to USFDA's warning letter for its two units
Last month, the company had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana
Dr Reddy's Laboratories has submitted a response to the US health regulator on a warning letter it had received last month.
"We would like to inform that the company has submitted a response to the US Food and Drug Administration (USFDA) on December 7", Dr Reddy's Laboratories said in a filing to the BSE.Last month, the country's second-largest drug maker had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.In response to the letter, DRL CEO G V Prasad had said the company is in the process of shifting some of the products from these plants to other facilities and considering third party assessment for its plants.The US agency had asked the drug maker to provide a comprehensive evaluation of the extent of inaccuracies in recorded and reported data and include a detailed action plan to fully investigate the scale and root causes of "deficient documentation and data management practices".PTI
India remains among fastest-growing major economies despite global uncertainty, says RBI Bulletin
Iran war could cut global growth by more than half: World Bank’s chief economist Indermit Gill
Brent crude climbs to $94 as analysts expect oil prices to stay in $90–100 range
UK inflation cools further to 2.6% in June as transport and food prices ease
India's gem and jewellery exports jump 26.5% in June on stronger global demand